



## **PRESS RELEASE**

### **Crucell Receives US Patent Covering its STAR™ Technology**

**Leiden, The Netherlands, April 5, 2005** – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has been granted a patent by the United States Patent and Trademark Office for its STAR™ technology.

The newly issued patent is the first and basic patent in a portfolio pertaining to the STAR™ technology developed by professor Arie Otte of Chromagenics B.V., a company acquired by Crucell in March 2004. The patent generally covers the identification and selection of so-called STAR™ sequences that find use in boosting the production of therapeutic proteins in cell-culture systems.

#### **About Crucell**

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with sanofi pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6® technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6® technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit [www.crucell.com](http://www.crucell.com).

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).*

#### **For further information please contact:**

##### **Crucell N.V.**

Leon Kruimer  
Chief Financial Officer  
Tel. +31-(0)71-524 8722  
[l.kruimer@crucell.com](mailto:l.kruimer@crucell.com)

##### **For Crucell in the US: Redington, Inc.**

Thomas Redington  
Tel. +1 212-926-1733  
[tredington@redingtoninc.com](mailto:tredington@redingtoninc.com)